EU medicines

PDUFA day for evolocumab (Repatha) at the US FDA

surfer The first PCSK9 inhibitor approved in the world stands before the FDA today for possible US approval. Evolocumab (brand name is Repatha) was approved by the European Medicines Agency (EMA) May 22, 2015.

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.